Delayed compared with early feeding in the initial hospital management of hyperemesis gravidarum
| ISRCTN | ISRCTN80694386 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN80694386 |
| Protocol serial number | 1206.12 |
| Sponsor | University of Malaya (Malaysia) |
| Funder | Universiti Malaya |
- Submission date
- 14/03/2016
- Registration date
- 16/03/2016
- Last edited
- 20/05/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Plain English summary of protocol
Background and study aims
Nausea and vomiting are common symptoms during early pregnancy, occurring in about 70–85% of pregnancies. Some pregnant women experience excessive nausea and vomiting, known as hyperemesis gravidarum, which leads to dehydration and significant weight loss. Hospitalisation is typically needed to rehydrate patients through a drip and to control nausea and vomiting with medication. In hyperemesis gravidarum, nausea may be triggered by just the thought of food, and vomiting often follows drinking or eating. In women recently hospitalised for hyperemesis it is not known whether there is benefit to a short (12 hour) delay in eating and drinking to allow rehydration and medication to take effect before eating and drinking is restarted. On the other hand, continuing to feed at the same time as rehydration and medication may permit the quickest recovery path. The aim of this study is to find out which is the better approach.
Who can participate?
Pregnant women aged 18 or over with hyperemesis gravidarum
What does the study involve?
Participants are randomly allocated to one of two groups. One group is encouraged eat and drink as soon as possible after hospitalisation. The other group is told to delay eating and drinking (fast) for the first 12 hours after hospitalisation, then resume eating and drinking at their own pace. Both groups receive intravenous rehydration (a drip), thiamine (vitamin) supplementation and anti-emetic (anti- vomiting) medication as standard inpatient treatment for hyperemesis gravidarum. Frequency of vomiting, nausea, patient satisfaction and duration of hospitalisation are measured.
What are the possible benefits and risks of participating?
We do not foresee any major benefits or significant risks. It is not clear which intervention will prove to be superior and there is a distinct likelihood the interventions may produce similar outcomes.
Where is the study run from?
University Malaya Medical Centre (Malaysia)
When is the study starting and how long is it expected to run for?
April 2016 to September 2017
Who is funding the study?
University of Malaya (Malaysia)
Who is the main contact?
Prof. Peng Chiong Tan
pctan@um.edu.my
Contact information
Public
Department of Obstetrics and Gynaecology
Faculty of Medicine
University of Malaya
Lembah Pantai
Kuala Lumpur
50603
Malaysia
| Phone | +60 (0)123 052 970 |
|---|---|
| pctan@um.edu.my |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Two-arm clinical trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Delayed compared with early oral intake in the initial manangement of hyperemesis gravidarum: a randomised trial |
| Study objectives | An initial 12-hour period of fasting (delayed oral intake) at hospitalisation for hyperemesis gravidarum to allow for hydration and anti-emetic medication to become effective compared to early feeding will result in less nausea and vomiting and higher patient satisfaction at 24 hours. |
| Ethics approval(s) | University Malaya Medical Centre Medical Ethics Committee, 04/02/2016, approval no. 1206.12 |
| Health condition(s) or problem(s) studied | Hyperemesis gravidarum |
| Intervention | Participants are randomized to: 1. Delayed oral intake (fasting) for the first 12 hours after hospitalisation for hyperemesis gravidarum followed by resumption of taking fluids and solids orally at the participants own pace 2. Encouraged to take fluids and solids orally as soon as, as much as and as often as tolerated after hospitalisation for hyperemesis gravidarum Both arms are to receive intravenous rehydration, oral thiamine supplementation and intravenous anti-emetic as standard inpatient treatment for hyperemesis gravidarum |
| Intervention type | Behavioural |
| Primary outcome measure(s) |
1. Frequency of vomiting in the first 24 hours |
| Key secondary outcome measure(s) |
1. Duration of hospitalisation |
| Completion date | 30/09/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Female |
| Target sample size at registration | 160 |
| Total final enrolment | 160 |
| Key inclusion criteria | 1. Clinical diagnosis of hyperemesis gravidarum 2. First hospitalisation for hyperemesis gravidarum in current pregnancy 3. Presence of ketonuria by urine dipstick (of 2+ or greater) at hospitalisation 4. At least 18 years of age 5. Pregnancy gestation of 14 weeks or less |
| Key exclusion criteria | 1. Multiple pregnancy 2. Molar pregnancy 3. Confirmed non-viable pregnancy 4. Any medical condition that contraindicates oral feeding or fasting |
| Date of first enrolment | 01/04/2016 |
| Date of final enrolment | 30/09/2017 |
Locations
Countries of recruitment
- Malaysia
Study participating centre
Kuala Lumpur
50603
Malaysia
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 30/04/2020 | 20/05/2020 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
20/05/2020: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.
18/10/2017: Internal review.
